Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

Código QR

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

Antoni Sicras-Mainar,1 Jorge Maurino,2 Elena Ruiz-Beato,3 Ruth Navarro-Artieda4 1Badalona Serveis Assistencials SA, Badalona, Spain; 2Medical Department, Roche Farma SA, Madrid, Spain; 3Health Economics and Outcomes Research Unit, Roche Farma SA, Madrid, Spain; 4Department of Medical Information,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/80ed5fd8eed64ed1a4a123da9d80e436
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
por: Sicras-Mainar A, et al.
Publicado: (2015)

Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia
por: Suttajit S, et al.
Publicado: (2013)

Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms
por: Urban-Kowalczyk M, et al.
Publicado: (2015)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Ibrahim Turkoz, et al.
Publicado: (2008)

Relationship between obesity and antipsychotic drug use in the adult population: A longitudinal, retrospective claim database study in Primary Care settings
por: Antoni Sicras-Mainar, et al.
Publicado: (2008)

Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
por: Cerveri G, et al.
Publicado: (2019)

One patient with Sjogren’s syndrome presenting schizophrenia-like symptoms
por: Lin CE
Publicado: (2016)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll CU, et al.
Publicado: (2020)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

Prevalence of Metabolic Syndrome According to Causes of Physical Activity Limitation
por: Lee K, et al.
Publicado: (2020)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko AS, et al.
Publicado: (2020)

A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
por: Liao X, et al.
Publicado: (2021)

Update on the management of symptoms in schizophrenia: focus on amisulpride
por: Ann M Mortimer
Publicado: (2009)

Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment
por: Iasevoli F, et al.
Publicado: (2013)

Cognitive dysfunction and negative symptoms in patients with schizophrenia and their first-degree relatives from simplex and multiplex families
por: Zhang Z, et al.
Publicado: (2018)

Measuring negative symptoms in patients with schizophrenia: reliability and validity of the Korean version of the Motivation and Pleasure Scale-Self-Report
por: Kim JS, et al.
Publicado: (2016)

Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
por: Gregory P. Strauss, et al.
Publicado: (2021)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
por: Aleksandr M. Reznik, et al.
Publicado: (2020)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
por: Wani RA, et al.
Publicado: (2015)

Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia
por: Terzić T, et al.
Publicado: (2015)

Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
por: Mackle M, et al.
Publicado: (2012)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
por: Wani RA, et al.
Publicado: (2015)

Influence of CFH gene on symptom severity of schizophrenia
por: Zhang C, et al.
Publicado: (2017)

Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2020)

Prevalence of bipolar spectrum disorder in Korean college students according to the K-MDQ
por: Bae SO, et al.
Publicado: (2013)

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
por: Giorgio L Colombo, et al.
Publicado: (2008)

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?
por: Suttajit S, et al.
Publicado: (2015)

Depressive symptoms and childhood sleep apnea syndrome
por: Carotenuto M, et al.
Publicado: (2012)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang X, et al.
Publicado: (2019)

The prevalence and risk factors of stroke in patients with chronic schizophrenia
por: Liang Y, et al.
Publicado: (2016)

Metacognitive Beliefs, Cognitive Functioning, Psychiatric Symptoms and Empathy in People with Schizophrenia
por: Chuang SP, et al.
Publicado: (2021)

Validation of the Dutch Version of the Brief Negative Symptom Scale
por: Seelen-de Lang BL, et al.
Publicado: (2020)

Prevalence and correlates of attention-deficit hyperactivity disorder symptoms in Korean college students
por: Kwak YS, et al.
Publicado: (2015)

Validation of the Chinese Version of the 16-Item Negative Symptom Assessment
por: Huang B, et al.
Publicado: (2020)

Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia
por: Albayarak Y, et al.
Publicado: (2015)

Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial
por: Zhuo K, et al.
Publicado: (2019)

Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia
por: Saruwatari J, et al.
Publicado: (2013)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018)

Associations between stress and depression symptom profiles vary according to serotonin transporter polymorphism in rural Australians
por: Sharpley CF, et al.
Publicado: (2018)

Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials
por: Michel Sabe, et al.
Publicado: (2021)